LSL Pharma Group Surges in Q1 with Record Profits

LSL Pharma Group Inc (TSE:LSL) has released an update.

LSL Pharma Group Inc. has announced a significant increase in Q1-2024 revenues, achieving $4.2 million, a 106% rise from the previous year, alongside a notable improvement in adjusted gross margins, which soared to $1.6 million, marking a 141% increase. The company also reported a successful transition from an operating loss to a profit, with an adjusted EBITDA of $0.65 million, and has strategically positioned itself for further growth by completing private placements worth $10.1 million and signing an acquisition agreement with a Quebec-based CDMO.

For further insights into TSE:LSL stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.